Dr Jordi Petriz na UMW

Dr Jordi Petriz  z Germans Trias i Pujol Research Institute (IGTP) w Hiszpanii będzie gościem seminarium naukowego "Clinical Applications of advanced Cytometry: a Focus on Anemia, leukemia, Immunotherapy and nanoplastic accumulation". Spotkanie odbędzie się w poniedziałek, 15 lipca na Wydziale Farmaceutycznym UMW.

Dr Jordi Petriz jest wybitnym europejskim specjalistą z zakresu cytometrii przepływowej oraz jej zastosowań w badaniach nad rakiem, oporności wielolekowej oraz wykorzystania komórek macierzystych m.in. w immunologii i hematoonkologii. 

Seminarium organizuje zespół Zakładu Podstaw Nauk Medycznych Katedry  Podstaw Nauk Medycznych i Immunologii Uniwersytetu Medycznego we Wrocławiu. Wstęp na spotkanie jest wolny. W imieniu organizatorów zapraszamy studentów UMW oraz pracowników uczelni i Uniwersyteckiego Szpitala Klinicznego we Wrocławiu.

Dr Jordi Petriz received his BSc degree in Biochemistry and Animal Biology from the University of Barcelona. He then pursued his PhD in Barcelona after being accepted at the Department of Cryobiology and Cell Therapy, Cancer Research Institute (IRO). In 1998, he obtained his PhD in Physiology and Immunology, specializing in function all based mechanisms of multidrug resistance to anticancer agents. The cytomic functional approach was used to study multidrug transporters and drug resistance profiling in highly refractory cancer cells. As a postdoctoral fellow, he applied novel cytomic approaches to address questions in whole blood CD34+ progenitor cell counting. In 2000, he joined the Subcommittee on Quality Assessment of Hematopoietic Stem Cell Grafts (established by the European Group for Bone Marrow Transplantation). Jordi Petriz has authored or co-authored nearly 100 research papers, including chapter books and proceedings, some in high-impact journals such as Nature Medicine and Leukemia. With a clear translational orientation, his current work focuses on minimizing the unwanted effects of sample preparation to allow improved study of live cells at the point of analysis, including some related to PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. He is a key opinion leader for Thermo Fisher Scientific, Sartorius Stedim and Sysmex. He has served as President of the Iberian Society of Cytometry (SIC) and as Councilor and Auditor of the European Society for Clinical Cell Analysis (ESCCA). He is also Associate Editor of Cytometry Part A, The Journal of Quantitative Cell Science.

More info >>